MASH and liver fibrosis: Clinical trials to watch.
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and hepatocellular carcinoma.
APA
Zhang X, Wong VW (2026). MASH and liver fibrosis: Clinical trials to watch.. Med (New York, N.Y.), 7(4), 101069. https://doi.org/10.1016/j.medj.2026.101069
MLA
Zhang X, et al.. "MASH and liver fibrosis: Clinical trials to watch.." Med (New York, N.Y.), vol. 7, no. 4, 2026, pp. 101069.
PMID
41966712
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and hepatocellular carcinoma. Conditional FDA approvals for resmetirom and semaglutide followed positive histological responses in recent trials, but full approval requires evidence of reduced major adverse liver outcomes. No drug is approved for MASH cirrhosis, a clear unmet need. This Trial Watch summarizes drug development landscape and promising therapeutic targets.
MeSH Terms
Humans; Liver Cirrhosis; Clinical Trials as Topic; Glucagon-Like Peptides; Fatty Liver; Carcinoma, Hepatocellular; Liver Neoplasms; Drug Development; Non-alcoholic Fatty Liver Disease; Drug Approval
같은 제1저자의 인용 많은 논문 (5)
- Effects of varicocele and microsurgical varicocelectomy on the metabolites in semen.
- Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia.
- IDH1 mutation creates a dependency on fatty acid metabolism that underlies sensitivity to cuproptosis in acute myeloid leukemia cells.
- E3 ubiquitin ligase DTX3L promotes breast cancer progression by enhancing PKCα ubiquitination and inhibiting the p38 MAPK signaling pathway.
- A Meta-Analysis: <em>PTEN</em> Expression in Relation to Prognosis and Clinical Characteristics of Patients with Colorectal Cancer.